União Europeia - espanhol - EMA (European Medicines Agency)

astrazeneca ab - de sodio de circonio cyclosilicate - hipercalemia - todos los demás productos terapéuticos - lokelma está indicado para el tratamiento de la hiperpotasemia en pacientes adultos.

União Europeia - espanhol - EMA (European Medicines Agency)

astrazeneca ab - glycopyrronium, formoterol fumarate dihydrate - enfermedad pulmonar, obstructiva crónica - el formoterol y el bromuro de glicopirronio - bevespi aerosfera está indicado como tratamiento broncodilatador de mantenimiento para aliviar los síntomas en pacientes adultos con enfermedad pulmonar obstructiva crónica (epoc).

União Europeia - espanhol - EMA (European Medicines Agency)

astrazeneca ab - andexanet alfa - relacionados con drogas efectos secundarios y reacciones adversas - todos los demás productos terapéuticos - para los pacientes adultos tratados con un directo del factor xa (fxa) inhibidor (apixaban o rivaroxaban) cuando la reversión de la anticoagulación es necesaria debido a que amenaza la vida o sangrado incontrolable.

União Europeia - espanhol - EMA (European Medicines Agency)

astrazeneca ab - formoterol fumarate dihydrate, glycopyrronium bromide, budesonide - enfermedad pulmonar, obstructiva crónica - medicamentos para la enfermedad obstructiva de las vías respiratorias enfermedades, - trixeo aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long acting beta2 agonist or combination of a long-acting beta2 agonist and a long acting muscarinic antagonist.

União Europeia - espanhol - EMA (European Medicines Agency)

astrazeneca ab - acalabrutinib - leucemia, linfocítica, crónica, b-cell - antineoplastic agents, protein kinase inhibitors, - calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll). calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.

União Europeia - espanhol - EMA (European Medicines Agency)

astrazeneca ab - moxetumomab pasudotox - leucemia, hairy cell - agentes antineoplásicos - lumoxiti as monotherapy is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (hcl) after receiving at least two prior systemic therapies, including treatment with a purine nucleoside analogue (pna).

União Europeia - espanhol - EMA (European Medicines Agency)

astrazeneca ab - tixagevimab, cilgavimab - covid-19 virus infection - prevention of covid-19.

União Europeia - espanhol - EMA (European Medicines Agency)

astrazeneca ab - anifrolumab - lupus eritematoso, sistémico - inmunosupresores - saphnelo is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (sle), despite standard therapy.

União Europeia - espanhol - EMA (European Medicines Agency)

astrazeneca ab - budesonide, formoterol fumarate dihydrate, glycopyrronium bromide - enfermedad pulmonar, obstructiva crónica - medicamentos para la enfermedad obstructiva de las vías respiratorias enfermedades, - riltrava aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2 agonist or combination of a long-acting beta2 agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.

União Europeia - espanhol - EMA (European Medicines Agency)

astrazeneca ab - tezepelumab - asma - medicamentos para la enfermedad obstructiva de las vías respiratorias enfermedades, - tezspire is indicated as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.